A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261
- Citation:
- Cancer vol 116 (24) 5686-5693
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 398
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-37, 404, U10 CA052352, CA-37, 417, CA-63, 848, U10 CA037417, CA-25, 224, CA-35, 195, U10 CA037404, U10 CA063848, U10 CA035195, 101, U10 CA035101, U10 CA035113, U10 CA035415, 415, CA-52, 352, U10 CA025224, 103, 113, U10 CA035103
- Corr. Author:
- Authors:
- Grace K. Dy Shauna L. Hillman Kendrith M. Rowland Julian R. Molina Preston D. Steen Donald B. Wender Suresh Nair Sumithra Mandrekar Steven E. Schild Alex A. Adjei
- Networks:
- Study
- NCCTG-N0326
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Article